Orthofix supplements SeaSpine merger disclosures with updated DCF and synergy projections

Orthofix Medical Inc.

Perella Weinberg DCF analyses updated: discount rates 9.75%-10.75%, perpetuity growth 3.0% for synergies.
SeaSpine standalone DCF range $2.93-$6.52 per share vs implied merger consideration $7.64 (Piper Sandler).
Orthofix standalone DCF range $18.15-$30.17 vs Orthofix closing price $18.34.
Piper Sandler fee estimated ~$4.3M contingent on deal closing; $1M opinion fee already paid.
Projected cost synergies: $42M in 2025E, rising to $50M in 2031E; stock-based comp synergies $8M in 2025E.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.